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Elin Sand1,2, Bodil Roth1, Bj?rn Westr?m 3, Peter Bonn4, Eva Ekblad2 and Bodil Ohlsson1*Abstract
Background: Women treated with gonadotropin-releasing hormone (GnRH) analogs may develop enteric neuropathy
and dysmotility. Administration of a GnRH analog to rats leads to similar degenerative neuropathy and ganglioneuritis.
The aim of this study on rat was to evaluate the early GnRH-induced enteric neuropathy in terms of distribution of
neuronal subpopulations and gastrointestinal (GI) function.
Methods: Forty rats were given the GnRH analog buserelin (20 μg, 1 mg/ml) or saline subcutaneously, once daily for
5 days, followed by 3 weeks of recovery, representing one treatment session. Two weeks after the fourth treatment
session, the animals were tested for GI transit time and galactose absorption, and fecal weight and fat content was
analyzed. After sacrifice, enteric neuronal subpopulations were analyzed. Blood samples were analyzed for zonulin and
antibodies against GnRH and luteinizing hormone, and their receptors.
Results: Buserelin treatment transiently increased the body weight after 5 and 9 weeks (p < 0.001). Increased estradiol
in plasma and thickened uterine muscle layers indicate high estrogen activity. The numbers of both submucous and
myenteric neurons were reduced by 27%? 61% in ileum and colon. The relative numbers of neurons containing
calcitonin gene-related peptide (CGRP), cocaine- and amphetamine-related transcript (CART), galanin, gastrin-releasing
peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS), serotonin, substance P (SP), vasoactive intestinal
peptide (VIP) or vesicular acetylcholine transporter (VAchT), and their nerve fiber density, were unchanged
after buserelin treatment, but the relative number of submucous neurons containing somatostatin tended to
be increased (p = 0.062). The feces weight decreased in buserelin-treated rats (p < 0.01), whereas feces fat content
increased (p < 0.05), compared to control rats. Total GI transit time, galactose absorption, zonulin levels in plasma, and
antibody titers in serum were unaffected by buserelin treatment.
Conclusions: A marked enteric neuronal loss with modest effects on GI function is found after buserelin treatment.
Increased feces fat content is suggested an early sign of dysfunction.
Keywords: Enteric neuropathy, Enteric subpopulations, Gastrointestinal (GI) tract, Gonadotropin-releasing hormone
(GnRH), Luteinizing hormone (LH), SomatostatinBackground
A subgroup of patients treated with gonadotropin-releasing
hormone (GnRH) analogs develops enteric neuropathy
with reduced relative number of GnRH-containing neu-
rons and dysmotility [1,2], and increased abdominal pain
and exacerbation of irritable bowel syndrome (IBS) has
been observed in a cohort of GnRH-treated women at
follow-up, although no obvious dysmotility was at hand* Correspondence: bodil.ohlsson@med.lu.se
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unless otherwise stated.[3]. This knowledge rendered us to set up an experimental
rat model to examine the effects on the gastrointestinal
(GI) tract of systemic and repeated treatment with the
GnRH analog buserelin. About 50% of enteric neurons
were lost throughout the GI tract after four treatment
periods of buserelin [4,5]. In addition, myenteric ganglia
displayed ganglioneuritis [5] and a significant reduction of
the relative number of luteinizing hormone (LH) receptor-
immunoreactive neurons [4]. In colon, a transient increase
in the relative number of vasoactive intestinal peptide
(VIP)-immunoreactive myenteric neurons was found after
two treatment periods, and increased relative numbers of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and myenteric neurons after four treatment periods [4].
The enteric nervous system (ENS) contains a plethora
of neurotransmitters, which all participate in the pivotal
role of ENS in controlling and modulating GI motility,
secretion, and blood flow. The neurotransmitters NOS, pitu-
itary adenylate cyclase-activating peptide (PACAP), purines,
somatostatin, and VIP mediate inhibitory transmission, while
excitatory transmitters represent acetylcholine, calcitonin
gene-related peptide (CGRP), cocaine- and amphetamine-
related transcript (CART), galanin, gastrin-releasing
peptide (GRP), neurokinin A, neuropeptide Y (NPY),
serotonin (5-hydroxytryptamine; 5-HT), and substance
P (SP) [6].
There is evidence of a high plasticity of the ENS in re-
sponse to injurious events in various experimental models,
e.g. axotomy, transplantation, hypertrophy, ischemia/
reperfusion, and lipopolysaccharide (LPS) challenge [7-11],
as well as in diseases [12,13]. Experimental rat models
of enteric neuropathy have been described, e.g. neur-
opathy after cisplatin-, diabetes-, or fat induction [14-16].
Most studies describe pathophysiology and morphological
changes in neuropathy, whereas few studies describe any
functional consequences on GI motility, nutritional ab-
sorption, and intestinal permeability.
The aim of the present study was to describe possible
early effects of buserelin-induced enteric neuronal loss
on subpopulations of neurons and on body weight, circu-
lating levels of sex hormones and antibodies, GI transit




Female Sprague? Dawley rats (n = 40, 170? 180 g), pur-
chased from Charles River, Sulzfeld, Germany, were used.
The rats were allowed to acclimatize to the climate- and
light-controlled animal facility for at least 5 days prior to
experimentation. Standard rat chow (4% fat/g) (Lactamin
R36, Stockholm, Sweden) and water were supplied at
all times. The experimental design was approved by the
Animal Ethics Committee, Lund and Malm?, Sweden
(M350-12, date of approval: 14.11.12). Animals were used
in accordance with the European Communities Council
Directive (2010/63/EU) and the Swedish Animal Welfare
Act (SFS 1988:534).
Study design
Twenty-four rats (n = 24) were given 20 μg (1 mg/ml) of
the GnRH analog buserelin (Suprefact?, Sanofi-Aventis,
Bromma, Sweden) subcutaneously, once daily for 5 days,
followed by 3 weeks of recovery, representing one ses-
sion of treatment (for details see ref no. [4]). The dosage
and administration of buserelin are based on previousstudies which have shown reliable physiological effects
in terms of uterine hypertrophy, without any adverse
effects [4,17]. Control animals (n = 16) received saline
injections. The animals were weighed prior to inclusion in
the study, and weekly in the morning during the study,
using an electronic scale. Half of the animals were used to
examine vaginal smears. From the other rats (12 buserelin-
treated and eight saline-treated controls), blood samples
were drawn in the morning before administration of buser-
elin or saline in week 1 and 4 of the injection treatment,
and at sacrifice. During the 2 weeks after the fourth treat-
ment session, GI transit time and galactose absorption
were studied. Feces were collected during 12 h of fasting
and analyzed for weight and fat content. After sacrifice,
tissue samples from the stomach, ileum, transverse colon,
and the distal part of the uterine horn were collected
and rinsed in saline before fixation and processing for
cryo- or paraffin-sectioning and histological evaluation.
All methods are described in detail below.
Blood and vaginal sampling
To study possible buserelin effects on the rat estrus cycle,
vaginal smears and blood samples for hormone measure-
ments were collected. On day 0 and 5 during session 1
and 4, vaginal smears were obtained using a cotton tipped
applicator, rotated three times, 2 cm from the vaginal ori-
fice. The vaginal smears were placed on microscope slides
and stained with methylene blue and eosin for determin-
ation of the phase in the estrus cycle. The classification of
the different cycles was performed according to estab-
lished criteria [18,19]. Briefly, proestrus is characterized by
a predominance of nucleated epithelial cells and estrus by
anucleated, cornified epithelial cells. Metestrus is charac-
terized by an equal portion of nucleated or anucleated epi-
thelial cells and leukocytes, while diestrus is characterized
by a predominance of leukocytes. Blood samples were
collected from the tail vein, using Li heparin tubes (BD
Microtainer, New Jersey, USA) and centrifuged at 3000 rcf
(1.12 ? R ? (RPM/1000) 2) for 5 min. Sera and plasma were
harvested and stored at −20?C. Samples were collected at
9:00 am before the first injection of buserelin or saline
(day 0), in the fourth session of injections (day 0 and 5),
and at sacrifice. Vaginal smears and blood samples taken
on day 0, before the first injection, served as an individual
control for each rat.
Tissue preparation
The gut segments and the uteri were opened and
embedded, flattened, in filter paper. One portion of each
gut segment was fixed in Stefanini ? s fixative (a mixture
of 2% formaldehyde and 0.2% picric acid in phosphate
buffer, pH 7.2) for 22 h at 4?C, and the other portion
and the uteri were fixed in 4% paraformaldehyde in
0.1 M phosphate buffer for 22 h at 4?C. Stefanini-fixed
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containing 10% sucrose, before being orientated and
mounted for longitudinal- and cross-sectioning in Tissue-
Tek (Sakura, Histolab, Gothenburg, Sweden), frozen on
dry ice, and sectioned (10 μm). Paraformaldehyde-fixed
specimens were dehydrated in ethanol, cleared in xylene,
orientated for longitudinal- and cross-sectioning, embed-
ded in paraffin, and sectioned (5 μm). Sections were proc-
essed for immunocytochemistry and histochemistry.
Histochemistry
Measurements of wall layer thickness were performed on
deparaffinized, hydrated, and hematoxylin-eosin-stained
paraffin sections from the uterus by using a computerized,
image-analyzing system (Imagescope, Aperio ScanScope
GL SS5082, Vista, CA 92081, USA). The myometrial
thicknesses to be measured were indicated manually, and
then measured using a computerized binary cursor. Mean
values of 6? 10 representative measurements were calcu-
lated from each rat.
Immunocytochemistry
For studies on enteric neuronal survival, antibodies against
human neuronal protein HuC/D (HuC/D) were used as
the general neuronal marker. Paraffin sections were depar-
affinized, hydrated, and subjected to antigen retrieval by
boiling in citrate acid buffer (0.01 M, pH 6) in a microwave
oven (650 W) for 2 ? 7 min. The sections were cooled and
washed in distilled water followed by phosphate-buffered
saline (PBS)/Triton. Sections were exposed to biotinyl-
ated, primary antibodies against HuC/D at 4?C overnight.
For visualization of biotinylated HuC/D, a VECTASTAIN
ABC kit containing horseradish peroxidase (HRP) and
3,3? -diaminobenzidine tetrahydrochloride (DAB) was used
(Vector Laboratories, Inc., CA, USA). HuC/D-immunoreactive
neurons stained dark brown and were counted in submu-
cous and myenteric ganglia on longitudinally-cut sections
using a computerized, image-analyzing system (Imagescope).
The number of HuC/D neurons in colon was counted in
scanned sections in a total length of at least 30 mm, cut at
6? 9 different depths per region and rat. Synthetic antigens
for testing the specificity of antibodies against HuC/D are
not commercially available. Thus, omission of the primary
antibodies was used as controls. Results are expressed as
numbers of submucous or myenteric neurons, immunore-
active to HuC/D, per mm length of GI tract.
To study whether the neuronal loss was general or spe-
cific regarding the subpopulations of enteric neurons, the
relative numbers of different subpopulations were studied
in colon, as this was the most affected region in the former
study [4]. Antibodies against CGRP, CART, galanin, GRP,
NPY, NOS, 5-HT, somatostatin, SP, VIP, in combination
with antibodies against HuC/D, were used on cryo sec-
tions. Since vesicular acetylcholine transporter (VAchT)immunoreactivity is mainly located on nerve fibers, anti-
bodies against VAchT alone, and not in combination with
HuC/D, were used on cryosections. Details on the anti-
bodies are given in Table 1. Absorption controls were per-
formed by adding an excess amount of antigen (10? 100 μg
of synthetic peptide diluted in antiserum) before exposure.
The sites of the antibody-antigen reactions were
visualized by exposure to a mixture of DyLight TM 488-
conjugated goat anti-mouse IgG serum and Alexa Fluor
TM 594-conjugated donkey anti-rabbit IgG serum, or
solely to Texas red donkey anti-goat (all diluted 1:1000;
Jackson ImmunoResearch Laboratories, Inc., Novakemi AB,
Handen, Sweden), for 1 h in room temperature (RT) and
then mounted in phosphate buffer:glycerol 1:1.
HuC/D-immunoreactive neurons also immunoreactive
to NOS, 5-HT or any of the neuropeptides tested, were
evaluated in cross- and longitudinally-cut, whole-wall sec-
tions. At least 150 submucous neurons and 250 myenteric
neurons were counted for each set of double-stains and
rat. The results are expressed as the percentage of HuC/
D-immunoreactive neurons also immunoreactive to NOS,
5-HT or any of the neuropeptides. Since VAchT immuno-
reactivity is mainly located on nerve fibers, the relative
number of VAchT-immunoreactive nerve cell bodies
could not be evaluated. Nerve fiber density was evaluated
on a 0, (+), +, ++, +++ scale, where 0 indicates no fibers,
(+) = occasional fibers, + = few fibers, ++ =moderate num-
bers of fibers, and +++ = numerous fibers.
Studies on gastrointestinal function
To measure total GI transit time, the rats fasted overnight
by removing their food at 9:00 pm. At 9:00 am the next
day, the rats were given a bolus dose (1 ml) of carbon sus-
pension trough gavage administered orally to the stomach
(150 mg/ml, Abigo Medical, Gothenburg, Sweden) before
being placed in separate cages with free access to food and
water. The rats were continuously and manually moni-
tored by staff being present all the time, until the first
carbon-containing fecal pellets were seen to be excreted.
In order to study fecal weight and fecal content [30],
feces were collected and weighed from all rats during the
12 h of fasting, prior to the measurement of GI transit
time, see above. The fecal samples were kept in open glass
tubes and left to dry at RT for 3 months in a fume cup-
board. The dry feces were ground in a mortar, transferred
to a 20 ml glass vial, and weighed. To extract the fat from
the feces, 10 ml of dichloromethane (DCM, Chromasolv,
Sigma-Aldrich, Stockholm, Sweden) was added. The mix-
ture was stirred vigorously for 1 h at RT. The DCM phase
was filtered with a plastic syringe (10 ml), fitted with a
polyethylene frit (20 μm, 10 ml, Biotage, Uppsala, Sweden)
and a syringe filter (1 μm, Acrodisc glass fiber, Pall, NY,
USA), and collected in a pre-weighed glass vessel. The ex-
traction procedure was repeated twice for a total of 30 ml
Table 1 Details on antibodies
Raised against Code no. Host Working dilution
cryosections
Supplier References
CART (61 ? 102) H-003-61 Rabbit 1:5000 Phoenix, GmBH, USA Ekblad et al. 2003;
Zacharko-Siembida et al. 2014 [20,21]
CGRP 8427 Rabbit 1:5000 Euro-Diagnostica, Sweden Ekblad et al. 1998 [8]
Galanin 8416 Rabbit 1:1000 Euro-Diagnostica, Sweden Ekblad et al. 1988; Ekblad et al. 1998 [8,22]
GRP R-6902 Rabbit 1:640 Ekblad et al. 1988 [22]
Hu proteins
(HuC/HuD)
A-2127 Mouse 1:600 Life Technologies, USA Lin et al. 2003 [23]
NOS 9223 Rabbit 1:5000 Euro-Diagnostica, Sweden Ekblad et al. 1994; Kristensson et al. 2007 [24,25]
C-PON* CA-08-300 Rabbit 1:3000 Genosys, UK Ekblad et al. 1988; Kristensson et al. 2007 [22,25]
Serotonin (5-HT) NSER Rabbit 1:1200 Inc. Star Corp, USA Mulder et al. 1997 [26]
Somatostatin 1758 Rabbit 1:3200 Kind gift from prof. J.J. Holst, Denmark Ekblad et al. 1988; Kristensson et al. 2007 [22,25]
Substance P (SP) SP7 Rabbit 1:800 Kind gift from prof. Emson, UK Lindestr?m et al. 2002 [ 27]
VIP 7854 Rabbit 1:2000 Euro-Diagnostica, Sweden Qian B et al. 2001; Kristensson et al. 2007 [25,28]
VAchT AB1578 Get 1:2000 Chemicon, USA Arvidsson U et al., 1997 [29]
*C-terminal flanking peptide of NPY (used for the detection of NPY-containing neurons).
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the solid material and the DMC were transferred to the
syringe. To ensure that as much as possible of the organic
solvent was filtered into the glass vessel, a plunger was
used to squeeze the solid material. The solvent was re-
moved by evaporation and the residue (fat content) was
weighed.
In order to study the absorptive capacity of galactose
after 12 h of fasting, a bolus dose of 1 ml of 5% galactose
dissolved in saline was given via a stomach tube as an
oral bolus dose under anesthesia. Blood samples were
collected in Li Heparin tubes from the tail vein using a
neoflon catheter, before and 10 min, 30 min, and 90 min
after the bolus dose [31]. Galactose levels in plasma were
analyzed with a BioVision ? s Galactose Assay Kit (K621-
100, BioVision Incorporated, CA, USA) according to the
manufacturer ? s protocol. Briefly, galactose is oxidized
using a galactose probe, an enzyme mix, and HRP, gen-
erating a colored product analyzed at the optic density
of 570 nm.
Serum analyses
Analyses of IgM- and IgG antibodies in serum against
GnRH, GnRH receptor (GnRHR), LH, and LH receptor
(LHR) were carried out in blood samples collected at sac-
rifice by an enzyme-linked immune sorbent assay (ELISA)
as described in detail previously [3]. Briefly, the wells
of microtiter plates (456537 Nunc, Roskilde, Denmark)
were either coated with human GnRH or N-terminal
GnRH-R peptide ((NH2)-ANSASPEQNQNHCSAINN
SIPLMQGNLPY) conjugated with ovalbumin (OVA)
(Innovagen, Lund, Sweden), 100 ng/well, in an over-
night incubation at 4?C. Thereafter, the plastic wellswere blocked with 0.5% bovine serum albumin (BSA)
(A-7030, Sigma, St Louis, USA) in PBS (10 mM PO4
3−,
137 mM NaCl, and 2.7 mM KCl, pH 7.4) containing
0.05% Tween-20 (PBS-T). The dilutions of patient serum
(1:400 in 1.0 μg OVA (A-5503, Sigma)/ml 0.5% BSA in
PBS-T) or mouse anti-human GnRH antibody (1.11 mg/
ml, ab62432, Abcam, Cambridge, MA, USA) in serial dilu-
tion (1:2 000? 1:32 000 to construct a standard curve) or
rabbit anti-human GnRHR antibody (90217.09, Innovagen)
in serial dilution (1:8 000? 1:128 000) were then added to
the plates and incubated for 2 h at RT. After rinsing with
PBS-T, deposition of antibodies directed to GnRH or
GnRHR was detected using the secondary antibodies rabbit
anti-rat IgG-biotin (ABCAM102170, Abcam, Cambridge,
MA, USA) or goat anti-rat IgM-biotin (ABCAM97178,
Abcam) diluted 1:10 000 in PBS-T.
Analysis of antibodies against LH was carried out
with intact, purified, native human LH (MBS537383,
MyBiosource, San Diego, CA, USA), 100 ng/well, in PBS
or only PBS-T (to provide an internal blank). After over-
night incubation at 4?C, the plates were washed three
times with PBS-T and blocked with 0.5% BSA in PBS-T.
Dilutions of serum (1:200) from patients and blood
donors, or rabbit anti-human LH antibody (MBS535386,
MyBiosource) in serial dilution (to construct a standard
curve), with BSA in PBS-T were then added to the plates
in triplicate (two wells coated with LH and one well coated
with PBS-T) and incubated for 2 h at RT. The washing
procedure was repeated and deposition of autoantibodies
directed to LH was detected using secondary antibodies as
described above, appropriately diluted in PBS-T.
Analysis of antibodies against the LHR was carried out
with the N-terminal LHR peptide ((NH2)-MKQRFSSALQL
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in 100 mM Carbonate buffer pH 9.2 or only Carbonate
buffer (to provide an internal blank). After overnight incu-
bation at 4?C, the plates were washed three times with
PBS-T and blocked with 0.5% BSA in PBS-T. Dilutions of
serum (1:200) from patients and blood donors with BSA
in PBS-T were then added to the plates in triplicate, two
to LHR and one to Carbonate buffer-coated wells, and
incubated for 2 h at RT. The washing procedure was
repeated and deposition of autoantibodies directed to
LHR was detected using secondary antibodies as described
above, appropriately diluted in PBS-T.
The absorbance at 405 nm was measured after 30 min
of incubation at RT. Antibody levels are expressed as
arbitrary units (AU) (absorbance values after subtracted
background levels and multiplied with 1000).Plasma analyses
Due to the small amount of rat plasma, all analyses were
performed with a single sample. Samples were analyzed ac-
cording to the manufacturer ? s instructions, and the result-
ing color changes were measured at the optical density of
450 nm. Each sample was interpolated from the standard
curve.
Follicle-stimulating hormone (FSH)-, 17β estradiol (E2)-,
and LH ELISA kits (MBS720215, MBS162143 and
MBS161787, respectively, MyBiosource, San Diego, CA,
USA) based on the double antibody sandwich technology
were used in plasma samples collected at study start and
during session 4. Plates were pre-coated with monoclonal
antibodies selectively recognizing rat FSH, E2 or LH. Stan-
dards of FSH: 2.5, 5.0, 10, 25, and 50 ng/ml; E2: 30, 60,
120, 240, and 480 ng/l; and LH: 31.2, 62.5, 125, 250, 500,
and 1000 ng/ml (to form a standard curve) or undiluted
rat heparin plasma samples were then added to the wells
on a microtiter plate (Nunc). A standardized preparation
of immune complexes in the form of HRP-conjugated
polyclonal antibody (FSH), or antibodies labeled with
biotin/streptavidin HRP (E2 and LH), were added.
A rat zonulin ELISA kit (MBS753035, MyBiosource)
based on the competitive enzyme immunoassay technique
was used to study epithelial integrity in plasma harvested at
sacrifice. The standards of 25, 50, 100, 250, and 500 ng/ml,
undiluted rat heparin plasma, and buffer were incubated
together with zonulin HRP conjugate on a plate pre-coated
with monoclonal anti-zonulin antibodies.Statistical analyses
All results are presented as medians (interquartile ranges
(IQR)), except weight, which is presented as mean ? standard
error of the mean (SEM). Statistical analyses were performed
by using the Mann? Whitney U-test. P < 0.05 was consid-
ered statistically significant.Results
General characteristics
One rat in each group was terminated because of admin-
istration to the lung of the oral galactose solution, leav-
ing 11 buserelin-treated (B) rats and seven saline-treated
control (C) rats for the analyses. The body weight gain
increased transiently in buserelin-treated rats in week 5
and 9 (p < 0.001; see Additional file 1). These time points
coincided with the end of the buserelin sessions 2 and 3.
The plasma levels of FSH were extremely low or undetect-
able in all rats (data not shown). The LH kit was unusable
on rat plasma and serum, as no standard curve could be
constructed. The estradiol levels in plasma were in the
same range at start (Day 0, session 1; C = 52 (41? 62) ng/L,
B = 55 (46? 58) ng/L), but during session 4, they were
elevated on day 0 and 5 in the buserelin-treated group,
reflecting that the hypothalamus-hypophys-gonadal axis
was not suppressed by buserelin treatment in this setting
(p < 0.05; for details see Additional file 2). At start (day 0,
session 1), the vaginal smears indicated that all rats were
unsynchronized in their estrus cycle (12 buserelin-treated
and eight saline-treated controls). After the first week of
treatment, the saline-treated rats were still unsynchro-
nized, while the buserelin-treated rats were all in metes-
trus or diestrus. In the fourth week of injection treatment,
the saline-treated rats were still unsynchronized on day 0
and 5, while the buserelin-treated rats were all in metes-
trus on day 0 and in diestrus on day 5 (see Additional
file 3). The uterine muscle layer was thicker in the group
of buserelin-treated rats compared to saline-treated con-
trols (p < 0.05; see Additional file 4).
Neuronal loss and neuronal subpopulations
Significant reductions in the absolute numbers of sub-
mucous neurons were detected in ileum and colon (27%,
p < 0.05 and 61%, p < 0.05, respectively). Of the myenteric
neurons, reduced numbers were noted in the stomach
(27%, p < 0.05), ileum (39%, p < 0.01), and colon (31%, p <
0.01). The loss of neurons was statistically more pro-
nounced in myenteric than in submucous ganglia, and
more pronounced in the colon and ileum than in the
stomach (Figure 1; for raw data see Additional file 5).
In colon, a small number (fewer than 10%) of submucous
nerve cell bodies were immunoreactive to CGRP, CART,
galanin, NPY or SP, while GRP-, NOS-, and VIP immuno-
reactivity were found in 10%? 43% of submucous neurons.
The relative number of somatostatin-immunoreactive sub-
mucous nerve cell bodies was 11% in colon from controls,
but showed a tendency to increase to 14% after buserelin
treatment (p = 0.062; Figure 2; for raw data see Additional
file 5). In both controls and buserelin-treated rats, few co-
lonic myenteric nerve cell bodies were found to contain
CGRP-, galanin-, NPY-, SP-, or VIP immunoreactivity,
and moderate numbers of neurons were found to contain
Figure 1 Numbers of neurons in submucous (SG) and myenteric ganglia (MG) per mm length of section in stomach (fundus), ileum,
and colon from rats treated with saline (C) or buserelin (B). Rats treated with buserelin showed decreased numbers of submucous neurons
in the ileum and colon, and myenteric neurons in the fundus, ileum, and colon. Cell-counting was performed on longitudinally-cut, whole-wall
sections. Results are presented as individual data and medians. Statistical analyses were performed using the Mann-Whitney U-test, C = 7 rats and
B = 9 ? 11 rats. Statistical significance is indicated by *p < 0.05 and **p < 0.01.
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immunoreactivity was abundant (Figure 2). Nerve cell
bodies immunoreactive to 5-HT was not detected, but a
sparse network of nerve terminals was found in the mu-
cosa and myenteric ganglia. The nerve fiber density was
not affected by buserelin treatment in any of the neuronal
subpopulations studied (Table 2). Pictures of immunos-
tainings of NOS and neuropeptides studied are shown in
Figure 3.
Studies on gastrointestinal function
Total feces weight decreased in buserelin-treated animals,
whereas total fat content per gram dried feces increased,
compared to control rats (Figure 4a and b; for raw data
see Additional file 5).
There was no difference in the total GI transit time be-
tween the buserelin-treated and the control rats, but a large
spread of individual values was noted within the buserelin-
treated group (Figure 5a). The area under the curve (AUC)
of absorbed galactose did not differ between the two
groups, but again, a large spread of individual values was
noted within the buserelin-treated group (Figure 5b).
Low titers of antibodies against GnRH, GnRHR, LH, and
LHR were found in serum in both groups (Figure 6a and b).
Plasma levels of zonulin were similar in both groups (C = 41
(32? 49) ng/ml; B = 34 (33? 38) ng/ml).Discussion
The present study confirms previous findings of a marked
loss of enteric neurons (27%? 61%) in rat appearing soon
after buserelin administration [4], with a tendency of in-
creased relative number of somatostatin-immunoreactive
submucous neurons. Buserelin caused increased estradiol
levels in plasma and thickened uterine muscle layers, indi-
cating high estrogen activity. Furthermore, the study re-
vealed that buserelin-treated rats had a decreased feces
weight with higher fat content, compared to controls. In
view of the marked buserelin-induced loss of enteric neu-
rons, the differences between buserelin-treated rats and
controls were surprisingly modest in the physiological
parameters investigated. The neuronal loss described
previously was most pronounced in colon [4], but in the
present study, the neuronal loss was the same in ileum as
in colon.
All rats had free access to food and water, except during
two short fasting periods. The decreased feces weight after
buserelin treatment is not easily explained by dehydration,
changed food intake or cachexia, as the body weight was
unaltered. Secretion of intestinal fluid is regulated mainly
by submucous ganglia [32]. The tendency to relative in-
crease in the number of submucous somatostatin neurons
seen in the present study might affect intestinal secretion,
since these most likely are cholinergic secretomotor
Figure 2 Relative numbers of immunoreactive neurons in submucous (SG) and myenteric (MG) ganglia in colon for calcitonin gene-related
peptide (CGRP), cocaine- and amphetamine-related transcript (CART), galanin (Gal), gastrin-releasing peptide (GRP), neuropeptide Y (NPY),
nitric oxide synthase (NOS), somatostatin (som), substance P (SP), and vasoactive intestinal peptide (VIP), expressed as % of human
neuronal protein HuC/D-immunoreactive neurons, from rats treated with four sessions of saline (C) or buserelin (B). Cell-counting
was performed on cross- and longitudinally-cut, whole-wall cryo sections, doubly immunostained for HuC/D and respective neuropeptide or NOS. With
the exception of submucous som-immunoreactive neurons, which showed a tendency to increase after buserelin treatment (p = 0.062), no differences
in any of the neuronal subpopulations were found between groups. Results are presented as individual data and medians. Statistical analyses were
performed by the Mann-Whitney U-test, C = 5? 6 rats and B = 10? 11 rats.
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http://www.biomedcentral.com/1471-230X/14/209neurons, also containing CGRP, issuing projections both
orally and anally to the mucosa and submucosa [6,33].
Increased somatostatin inhibitory input could lead to re-
duced secretomotor activity, leading to reduced fluids in
the lumen and feces, affecting fecal water content and
fecal weight.
The most plausible explanation for the higher percentage
of fat in the feces of buserelin-treated rats is maldigestion
and/or malabsorption of dietary fat. The regulatory mecha-
nisms of digestion and absorption of fat are complex, withTable 2 Nerve fiber density and distribution in colon was ide
CGRP CART Gal GRP NPY
M (+) ++ ++ ++ ++
SM (+) + ++ ++ +++
SG + ++ +++(+) +++ ++
MG + +++ +++ +++ ++
CM (+) ++++ +(+) + ++
LM (+) + (+) + ++
BV (+) (+) 0 0 +++
The colon mucosa (M), submucosa (SM), submucous ganglia (SG), myenteric ganglia (M
evaluated separately. The density and distribution of nerve fibers immunoreactive to ca
(CART), galanin (Gal), gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide
intestinal peptide (VIP), and vesicular acetylcholine transporter (VAchT) in colon of saline
density and distribution were found between groups. Nerve fiber density was evaluated
+ = few fibers, ++ = moderate numbers of fibers, and +++ = numerous fibers. n = 5? 11several neural short and long reflexes involving an intri-
cate synchronization of intestinal motility and secretion,
gallbladder contraction, exocrine pancreas secretion, and
hormone release from endocrine cells. An intact neural
function is crucial for the regulation of gut peptide secre-
tion from endocrine cells, and for emptying of bile and
pancreatic enzymes into the intestinal lumen [34,35].
In the present study, no increase of the relative numbers
of VIP- or NOS-immunoreactive neurons were found,
when the rats were euthanized 2 weeks after the end ofntical in saline- and buserelin-treated rats
NOS 5-HT Som SP VIP VAchT
+ (+) + (+) +++ (+)
+ 0 + (+) +++ (+)
++ 0 + (+) +++ +
+++ + + ++ ++ ++
+++(+) 0 (+) (+) ++ (+)
+ 0 (+) (+) + +
(+) 0 + 0 (+) 0
G) circular (CM) and longitudinal (LM) muscle layers, and blood vessels (BV) were
lcitonin gene-related peptide (CGRP), cocaine- and amphetamine-related transcript
synthase (NOS), serotonin (5-HT), somatostatin (Som), substance P (SP), vasoactive
- and buserelin-treated rats are shown combined as no differences in nerve fiber
on a 0, (+), +, ++, +++ scale, where 0 indicates no fibers, (+) = occasional fibers,
.
Figure 3 Cryo sections of colon from rats treated with saline (b, c, e, g, j) or buserelin (a, d, f, h) immunostained with human neuronal
protein HuC/D (green) and calcitonin gene-related peptide (CGRP), cocaine- and amphetamine-related transcript (CART), galanin,
gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS), somatostatin (som), substance P (SP), and
vasoactive intestinal peptide (VIP)(red). Micrographs are merged and show intense immunostaining, irrespective of treatment. Arrowheads
indicate HuC/D-immunoreactive myenteric neurons also immunoreactive to CGRP (a), CART (b), and NOS (f). Arrows indicate a HuC/D-immunoreactive
submucous neuron also immunoreactive to galanin (c), GRP (d), NPY (e), som (g), and VIP (j). In micrograph (h), SP-immunoreactive fibers innervate a
myenteric ganglia. Scale bar = 20 μm applies for all the micrographs in Figure 3.
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http://www.biomedcentral.com/1471-230X/14/209the fourth session. In our previous study of colon, a
significant increase of myenteric VIP-containing neurons
was found after two sessions of buserelin treatment, and
in both submucous and myenteric NOS-immunoreactive
neurons after four sessions of treatment, when rats were
euthanized immediately after the fourth treatment [4].Figure 4 Fecal weight (a) and fecal fat (b) in saline (C)- and buserelin
fasting. Feces from buserelin-treated rats had a lower weight (g) compared
Buserelin-treated rats had an increased weight percentage of fat in feces c
and medians. Statistical analyses were performed by the Mann-Whitney U-t
*p < 0.05 and **p < 0.01.This suggests that 2 weeks post treatment, the acute neur-
onal/tissue impingement has subsided, since increased
expression of VIP and NOS are early signs of an injurious
event, e.g. lipopolysaccharide (LPS) challenge, axotomy or
after ischemia followed by reperfusion [7,10,11]. In gen-
eral, the relative numbers of neurons immunoreactive to(B)-treated rats. Feces were collected and weighed after 12 h of
to feces from saline-treated rats. Fecal fat was analyzed on dried feces.
ompared to saline-treated rats. Results are presented as individual data
est, C = 7? 8 and B = 10? 12 rats. Statistical significance is indicated by
Figure 5 Gastrointestinal (GI) transit time (a) and total concentration of absorbed galactose (μM*h, area under curve (AUC)) (b) in
saline (C)- and buserelin (B)-treated rats. No difference in total GI transit time was noted (a). The AUC of galactose in plasma did not differ
between the two groups (b). Results are presented as individual data and medians. Statistical analyses were performed by using the Mann-Whitney
U-test, C = 7 and B = 11 rats.
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http://www.biomedcentral.com/1471-230X/14/209CGRP, CART, galanin, GRP, NPY, NOS, 5-HT, SP, VIP or
VAchT, and their nerve fiber density, were unaffected by
buserelin treatment. This implies that the neuronal loss is
nonselective to subpopulations. It also strengthens the
concept that ENS is highly adaptive and strives to main-
tain its original set of neuronal subpopulations, as well as
its distribution and density of nerve terminals.
Although the enteric neuronal loss was most pro-
nounced in the myenteric ganglia, the GI transit time
and galactose absorption were generally not affected by
repeated buserelin treatments. A greater inter-individual
difference was seen in buserelin-treated rats, in analogy
to the inter-individual effect on GI function observed in
women after treatment with a GnRH analog [2,3,36]. The
transport protein called sodium-glucose transport protein
1 (SGLT-1) is used by enterocytes to absorb both galactose
and glucose, and the glucose transporter protein (GLUT2)
is located basally for export [37,38]. The absorption of
nutrients is a vital mechanism depending mainly on the
function and integrity of the intestinal mucosa, while
intestinal innervation plays a minor role, probably explain-
ing the lack of effect on absorption in the current study.
Initial administration of a GnRH analog in man leads
to increased secretion of FSH and LH, whereas continu-
ous stimulation leads to receptor desensitization and
down-regulation of gonadotropin secretion after 10 days
of treatment [39]. The LH secretion in female rats starts
in proestrus, peaks in the evening, resulting in ovulation,
and shows low levels next morning (estrus). FSH- and LH
secretions start simultaneously, but FSH remains elevated
throughout the estrus [40,41]. The FSH- and LH levels are
very low during the rest of the reproductive cycle [41],
and are secreted in a pulsatile manner, like GnRH [42]. Al-
though plasma FSH was not measureable in the present
study, when the animals were in other cycles than proes-
trus and estrus, the combination of elevated estradiol
levels in plasma, thickened uterine muscle layers, and syn-
chronized reproductive phases in buserelin-treated rats
indicate a GnRH influence on the hypothalamus, leading
to enhanced FSH- and LH secretion with ensuing estradiolsecretion. From another study, the buserelin-induced
loss of enteric neurons is suggested to be mediated via
LH receptor activation, since the relative number of LH
receptor-expressing myenteric neurons was decreased
after buserelin treatment, and neither GnRH nor its recep-
tor could be identified in the ENS of the rat [4].
As there was no difference in the prevalence of circu-
lating antibodies against GnRH, LH, and their receptors
between groups, the noted enteric neuropathy is prob-
ably not mediated by autoantibodies. GnRH has been
found in enteric neurons in man, and the expression of
GnRH antibodies after buserelin-induced dysmotility is
probably secondary to the marked neuropathy [1,2], as
antibody prevalence and titer were the same before and
after buserelin treatment [3]. Alpha- and beta estrogen
receptors are expressed in enteric neurons [43], and the-
oretically, estradiol could exert degenerative effects on
the ENS. However, estrogens are widely used in contra-
ceptives and hormonal replacement therapies, without
any reports of ensuing dysmotility. The mechanism be-
hind the buserelin-induced neuropathy needs to be fur-
ther evaluated, for example, in cell culture experiments
using primary enteric neurons.
Zonulin participates in the physiological regulation of
intercellular tight junctions in the small intestine. Dys-
regulation of the zonulin pathway may lead to intestinal
disorders, and elevated zonulin levels in serum are re-
ported in untreated celiac disease [44]. Similar plasma
levels of zonulin in saline- and buserelin-treated rats, as
found in the present study, suggest that gut mucosa
integrity is mainly uncompromised by the buserelin-
induced neuropathy.
In the daily clinical work, tests on nutrient absorption
and analyses of fat in feces are never or seldom performed.
The degree of fat malabsorption can be evaluated, but it is
a rough estimation, and is primarily used to reveal exo-
crine pancreatic insufficiency or severe epithelial dysfunc-
tion, e.g. celiac disease. About half of the patients with GI
complaints, consulting a gastroenterology ward, are diag-
nosed as suffering from IBS [45]. The etiology behind IBS
Figure 6 Circulating antibodies. a. Circulating IgG- and IgM antibodies against gonadotropin-releasing hormone (GnRH) and its receptor
(GnRHR) in saline (C)- and buserelin (B)-treated rats. Low titers (arbitrary units (AU)) of antibodies were found in both saline- and buserelin-treated
rats, with no differences between the groups. Results are presented as individual data and medians. Statistical analyses were performed by using
the Mann-Whitney U-test, C = 7 and B = 11 rats. b. Circulating IgG- and IgM antibodies against luteinizing hormone (LH) and its receptor (LHR) in
saline (C)- and buserelin (B)-treated rats. Low titers (arbitrary units (AU)) of antibodies were found in both saline- and buserelin-treated rats, with
no differences between the groups. Results are presented as individual data and medians. Statistical analyses were performed by using the
Mann-Whitney U-test, C = 7 and B = 11 rats.
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reveal objective parameters explaining the dysfunction.
Affective disturbances and psychiatric disorders are com-
mon, concomitant diagnoses with IBS [45]. Examinations
show that IBS patients are associated with an enhanced
perception of personal vulnerability to illness [47], and they
often over-report symptoms and suffer from somatization
disorders [48,49]. Functional magnetic resonance imaging
(fMRI) reveals significant differences in the neural process-
ing of pain between IBS patients and controls, further
underlining the importance of psychological factors in the
pathophysiology of visceral hypersensitivity in these pa-
tients [50,51]. The results in the present study make the
possibility feasible that severe, unrevealed enteric neuro-
degeneration exists in subgroups of IBS patients. Different
etiologies for the GI symptoms may explain the difficulties
to find conclusive explanations in scientific reports.
Chronic abdominal complaints may be a stress factor for
the patient, leading to an abnormal central processing of
the pain [50,51], and thus, psychological and cognitive
dysfunctions in IBS may be secondary, rather than causal.
A tendency of an increase in the relative number of
somatostatin-immunoreactive submucous neurons was
found in our present study. This is interesting since the
transient receptor potential vanilloid 1 (TRPV1), which is
involved in visceral pain signaling, is up-regulated in IBS
patients where it stimulates increased release of somato-
statin and SP [52]. Patients who had undergone several
IVFs with buserelin treatments suffered from more ab-
dominal pain and exacerbation of IBS 5 years after than
prior to treatment, although no obvious dysmotility was
found [3]. As the ENS seems to have a huge reserve of
functional capacity, the treated patients may acquire a
modest, but subclinical, enteric neuropathy making them
more vulnerable to complications in, for instance, diabetes
mellitus and neurological diseases.
Conclusion
A marked enteric neuronal loss with modest effects on GI
function is found after buserelin treatment. Increased feces
fat content is suggested an early sign of dysfunction.
Additional files
Additional file 1: Body weights. Body weight over time studied on rats
treated with one to four sessions with saline (C, −○) or buserelin (B, −●).
One session consists of 5 days of treatment, with one daily subcutaneous
injection of saline or buserelin, followed by 3 weeks recovery. All rats were
healthy and gained weight throughout the experimentation. At the end
of the second and third treatments (weeks 5 and 9), buserelin-treated rats
showed a transient increase in weight compared to saline-treated rats.
Results are presented as means and standard error of the mean (SEM)
and analyzed by Mann-Whitney U- test, C = 7 and B = 12. Statistical
significance is indicated by ***p < 0.001.
Additional file 2: Plasma estradiol levels. Estradiol (E2) plasma levels
in rats, day 0 and 5, of the fourth treatment session with saline (C) orbuserelin (B). The rats receiving buserelin had already high levels of
estradiol, at start of the last treatment session (session 4) compared
to saline-treated rats (p < 0.05). Estradiol levels were still high day 5
in buserelin- compared to saline-treated rats (p < 0.05), indicating a
sustained buserelin-induced high estrogen activity. Results are presented
as medians and analyzed by Mann-Whitney U -test, C = 6 and B = 12.
Statistical significance is indicated by *p < 0.05.
Additional file 3: Vaginal smear characterization. Effects of buserelin
or saline in individual rats on their estrus cycle. Vaginal smears were
collected day 0 and 5 during session 1 and 4. The classification of the
different phases in estrus cycle were performed according to established
criteria (Freeman 2006, Maldonao-Devinci 2010): - Proestrus (Pro) is
characterized by the predominance of nucleated epithelial cells. - Estrus (E)
is characterized by the predominance of anucleated cornified cells. -
Metestrus (M) is characterized by an equal portion of nucleated and
anucleated epithelial cells and leukocytes. - Diestrus (D) is characterized by
the predominance of leukocytes.
Additional file 4: Thickness of uterine muscle layers. Thicknesses of
uterine muscle layer in rats treated with four sessions of saline (C) or
buserelin (B). Buserelin-treated rats had hypertrophic uterine muscle
layers compared to saline-treated rats. Results are presented as medians
and analyzed by Mann-Whitney U- test, C = 5 and B = 12. Statistical
significance is indicated by p < 0.05, which was considered statistically
significant.
Additional file 5: Raw data. The number of enteric neruons in
submucous ganglia (SG) and myenteric ganglia (MG) of fundus, ileum,
and colon. The values of feces weight (g) and fat content (% of dried
feces) are given. The number of immunoreactive neurons in submucous
ganglia (SG) in colon for somatostatin (som), expressed as % of human
neuronal protein HuC/D-immunoreactive neurons, from rats treated with
four sessions of saline (controls) or buserelin. Link to the journal
guidelines: http://www.biomedcentral.com.
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